Semaglutide (Ozempic) raises questions about mood and nonresponse
1. Reports of emotional flattening among some users of semaglutide (Ozempic) have brought new attention to how glucagon-like peptide-1 receptor ...
Tag: obesity medicine
Lilly’s retatrutide achieves significant weight loss and A1C reduction in Phase 3 trial
1. Retatrutide met all major Phase 3 endpoints, delivering substantial reductions in both A1C and body weight in patients with ...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]
Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer Topline results from the Phase 3 TALAPRO-3 study indicate that ...
